Your browser doesn't support javascript.
loading
Cardiac resynchronization therapy for the treatment of heart failure in patients with intraventricular conduction delay and malignant ventricular tachyarrhythmias.
Higgins, Steven L; Hummel, John D; Niazi, Imran K; Giudici, Michael C; Worley, Seth J; Saxon, Leslie A; Boehmer, John P; Higginbotham, Michael B; De Marco, Teresa; Foster, Elyse; Yong, Patrick G.
Affiliation
  • Higgins SL; Scripps Memorial Hospital, La Jolla, California 92038-0028, USA. EPDocHiggins@msn.com
J Am Coll Cardiol ; 42(8): 1454-9, 2003 Oct 15.
Article in En | MEDLINE | ID: mdl-14563591
OBJECTIVES: This study was conducted to assess the safety and effectiveness of cardiac resynchronization therapy (CRT) when combined with an implantable cardioverter defibrillator (ICD). BACKGROUND: Long-term outcome of CRT was measured in patients with symptomatic heart failure (HF), intraventricular conduction delay, and malignant ventricular tachyarrhythmias (ventricular tachycardia/ventricular fibrillation [VT/VF]) requiring therapy from an ICD. METHODS: Patients (n = 490) were implanted with a device capable of providing both CRT and ICD therapy and randomized to CRT (n = 245) or control (no CRT, n = 245) for up to six months. The primary end point was progression of HF, defined as all-cause mortality, hospitalization for HF, and VT/VF requiring device intervention. Secondary end points included peak oxygen consumption (VO(2)), 6-min walk (6 MW), New York Heart Association (NYHA) class, quality of life (QOL), and echocardiographic analysis. RESULTS: A 15% reduction in HF progression was observed, but this was statistically insignificant (p = 0.35). The CRT, however, significantly improved peak VO(2) (0.8 ml/kg/min vs. 0.0 ml/kg/min, p = 0.030) and 6 MW (35 m vs. 15 m, p = 0.043). Changes in NYHA class (p = 0.10) and QOL (p = 0.40) were not statistically significant. The CRT demonstrated significant reductions in ventricular dimensions (left ventricular internal diameter in diastole = -3.4 mm vs. -0.3 mm, p < 0.001 and left ventricular internal diameter in systole = -4.0 mm vs. -0.7 mm, p < 0.001) and improvement in left ventricular ejection fraction (5.1% vs. 2.8%, p = 0.020). A subgroup of patients with advanced HF (NYHA class III/IV) consistently demonstrated improvement across all functional status end points. CONCLUSIONS: The CRT improved functional status in patients indicated for an ICD who also have symptomatic HF and intraventricular conduction delay.
Subject(s)
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Pacemaker, Artificial / Ventricular Fibrillation / Cardiac Pacing, Artificial / Tachycardia, Ventricular / Defibrillators, Implantable / Heart Conduction System / Heart Failure Type of study: Clinical_trials Aspects: Patient_preference Limits: Aged / Female / Humans / Male Language: En Journal: J Am Coll Cardiol Year: 2003 Document type: Article Affiliation country: United States Country of publication: United States
Search on Google
Collection: 01-internacional Database: MEDLINE Main subject: Pacemaker, Artificial / Ventricular Fibrillation / Cardiac Pacing, Artificial / Tachycardia, Ventricular / Defibrillators, Implantable / Heart Conduction System / Heart Failure Type of study: Clinical_trials Aspects: Patient_preference Limits: Aged / Female / Humans / Male Language: En Journal: J Am Coll Cardiol Year: 2003 Document type: Article Affiliation country: United States Country of publication: United States